Oncology Drugs PNLE Questions

Introduction

Tangerine's live inventory contains exactly 10 original PNLE-style practice questions for Oncology Drugs; the inventory was last updated August 12, 2026. These items focus on antineoplastic and chemotherapy regimens and the supportive care decisions attached to those regimens.

Use this topic to practice linking a drug or class with the cue that changes nursing action: assess for regimen-specific toxicity, recognize an urgent symptom, verify a dose or safe-handling step, and escalate findings through the appropriate oncology protocol. The scope includes chemotherapy-related monitoring, PPE, body-surface-area dosing checks, and class- or drug-linked complications. A generic adverse effect without a regimen or class focus belongs in Adverse Effects & Toxicology, while nearby questions may require distinguishing Oncology Drugs from Hematologic Drugs or Immunologic & Transplant Drugs.

Oncology Drugs is a Tangerine lens within NP7: Pharmacology. It is mapped across relevant competencies in the official five-subject PNLE TOS, including the 2025 Enhanced TOS; it is not a separate official test subject. The TOS supplies broad competency relationships, so it does not assign a guaranteed weight or question count to this microtopic, and the exact distribution varies by exam form.

Key concepts

Regimen-specific urinary safety
Recognize: With cyclophosphamide, hematuria, dysuria, urinary frequency, or suprapubic discomfort may signal bladder injury rather than an expected minor complaint.
Decide: Assess promptly, document the finding, notify the oncology team according to protocol, and verify the ordered hydration or mesna plan.
Avoid: Reassuring the patient without assessment or independently adding supportive treatment that is not ordered.
Vincristine classification and neurotoxicity
Recognize: Vincristine is a vinca alkaloid that disrupts microtubule function; numbness, weakness, reduced reflexes, constipation, or ileus are important cues.
Decide: Assess neurologic and bowel status, verify the prescribed route and line safety, and escalate worsening findings.
Avoid: Treating classification as a memorization endpoint or overlooking the critical safety rule that vincristine must never be given intrathecally.
Doxorubicin-related cardiac concern
Recognize: New dyspnea, edema, palpitations, unusual fatigue, or reduced activity tolerance during a doxorubicin regimen can require evaluation for cardiac toxicity.
Decide: Assess cardiopulmonary status and report concerning changes through the regimen's monitoring pathway.
Avoid: Labeling every new symptom as routine chemotherapy discomfort without connecting it to the named drug.
Urgent symptoms during tamoxifen therapy
Recognize: Sudden chest pain or dyspnea, unilateral leg pain or swelling, or focal neurologic changes may indicate a serious thromboembolic event.
Decide: Treat these findings as urgent, assess immediately, and activate the appropriate response rather than waiting for a routine follow-up.
Avoid: Focusing only on common expected effects when the stem supplies a red-flag symptom.
Body-surface-area dose verification
Recognize: Pediatric chemotherapy calculations may depend on current height, weight, units, body surface area, and the prescribed dose per m2.
Decide: Recheck the source measurements, calculation, regimen order, and independent medication check before administration.
Avoid: Estimating from age alone, carrying forward an outdated measurement, or accepting a rounded result without verification.
Hazardous-drug handling
Recognize: Preparation, administration, spill management, and contact with contaminated materials require attention to the facility's hazardous-drug procedures.
Decide: Use the required PPE, disposal process, and exposure-response steps for the specific task, product, and institutional policy.
Avoid: Assuming ordinary medication precautions are sufficient or improvising after a spill or exposure.
Class-linked pulmonary toxicity
Recognize: When a stem names a chemotherapy drug or regimen and reports new cough, dyspnea, or an oxygenation change, the symptom may represent a regimen-related toxicity.
Decide: Assess the respiratory change, compare it with baseline, and escalate according to the prescribed oncology pathway.
Avoid: Memorizing a symptom without the drug or class context, because a generic adverse-effect question belongs in the adjacent Adverse Effects & Toxicology topic.

What to expect on the PNLE

The live inventory contains 10 questions, with easy=3, medium=4, and hard=3. Its Bloom distribution is remembering=4, applying=3, evaluating=2, and analyzing=1, so practice should include both direct recall and decisions based on clinical cues.

Inventory titles support several question forms: identifying a drug classification, calculating pediatric chemotherapy by body surface area, selecting PPE for chemotherapy handling, recognizing regimen-linked toxicity, and identifying an adverse effect that requires urgent reporting. The cognitive work includes recalling a class, applying a calculation or safety procedure, evaluating whether a symptom needs escalation, and analyzing the relationship between a named drug and a complication.

Read for the anchor: Find the drug, class, regimen, route, measurement, or task that controls the decision.
Read for the consequence: Decide whether the cue requires assessment, immediate reporting, dose verification, route protection, or hazardous-drug precautions.
Protect the scope: Keep a generic adverse effect separate from a question that names a chemotherapy regimen or class.
Interpret the inventory correctly: These counts describe the supplied practice set, not a guaranteed board-exam blueprint. Exact topic distribution varies by exam form.

Study tips

Start with diagnostic practice. Answer all 10 live Oncology Drugs questions without notes. For every item, mark both your answer confidence and the decision cue you used, such as a named drug, an urgent symptom, a calculation detail, or a handling task.
Use focused retrieval. Make a comparison grid from memory with these columns: drug or class, signature toxicity or safety issue, cue in the stem, immediate nursing decision, and supportive-care check. Include cyclophosphamide, vincristine, doxorubicin, tamoxifen, BSA dosing, and hazardous-drug handling.
Comparison grid
Drug or class | Key cue | Nursing decision | Supportive-care or safety check
Cyclophosphamide | Urinary change | Assess and escalate | Verify ordered hydration or mesna
Vincristine | Neurologic or bowel change | Assess and report | Verify route and line safety
Review rationales and errors. For each missed or guessed question, write the exact cue you missed, the unsafe action your choice could cause, and the scope boundary that applies. Separate a remembering error, such as drug classification, from an applying or evaluating error, such as choosing the safest response.
Retry with spacing. Revisit the grid and missed questions after a gap, then explain each answer aloud before looking at the rationale. Replace vague notes such as chemotherapy causes toxicity with a regimen-linked statement that names the cue and the action.
Finish with mixed timed practice. Combine Oncology Drugs with Hematologic Drugs, Immunologic & Transplant Drugs, and Adverse Effects & Toxicology. After the set, sort errors by recognition, calculation, escalation, or safe handling so the next review targets the weakest decision process.

Common mistakes to avoid

Calling every symptom an expected chemotherapy effect. This ignores the scope rule. Correct the error by linking the symptom to the named drug or regimen and asking whether it changes monitoring, escalation, or treatment safety.
Recognizing cyclophosphamide but missing the urinary cue. Hematuria, dysuria, or new urinary frequency should prompt assessment for bladder injury and timely reporting. Do not wait for severe pain before acting.
Choosing the vincristine classification without applying route safety. A correct drug class does not replace safe administration reasoning. Recheck the route and line requirements, assess neurotoxicity and bowel function, and remember that intrathecal administration is prohibited.
Relying on an unverified chemotherapy calculation. Using an old weight, inconsistent units, or an unchecked BSA result can produce a harmful dose. Use current measurements, the prescribed dose basis, and an independent verification process.
Using routine medication PPE for hazardous chemotherapy tasks. Preparation, administration, spills, and contaminated materials may have different precautions. Follow the specific institutional hazardous-drug procedure instead of selecting equipment from memory.
Delaying urgent symptom reporting. Sudden respiratory or thromboembolic-type symptoms during a named oncology regimen require prompt assessment and escalation. A reassuring appearance or an assumption that the symptom is temporary is not a sufficient safety check.

Try a question

A real Oncology Drugs question from our bank. Give it a shot.

Medium

A patient is receiving cyclophosphamide. Which finding should the nurse recognize as most suggestive of hemorrhagic cystitis?

A

Fever accompanied by a markedly reduced neutrophil count

B

Dysuria accompanied by visible blood in the urine

C

Persistent vomiting accompanied by poor oral intake

D

Mouth ulcers accompanied by pain when swallowing

Rationale

Cyclophosphamide is an alkylating chemotherapeutic agent well recognized for its potential to cause hemorrhagic cystitis, a serious bladder complication characterized by inflammation and bleeding of the bladder mucosa. Understanding the signs, pathophysiology, and priority nursing actions associated with cyclophosphamide therapy is essential for patient safety.

Option	Analysis
A	Fever with severe neutropenia is suggestive of myelosuppression or neutropenic fever, a known adverse effect of many chemotherapeutics but not specific to hemorrhagic cystitis. While serious, it does not indicate bladder inflammation or bleeding.
B	Dysuria (painful urination) with visible blood in the urine (gross hematuria) directly points to hemorrhagic cystitis. Cyclophosphamide's toxic metabolites are excreted in urine, irritating the bladder mucosa and causing bleeding. These are hallmark signs requiring urgent intervention—prompt hydration and mesna administration can help prevent or minimize bladder toxicity.
C	Persistent vomiting and poor oral intake suggest gastrointestinal toxicity or nausea, but these findings do not specifically indicate bladder involvement or hemorrhagic cystitis.
D	Mouth ulcers and painful swallowing suggest mucositis or stomatitis, another potential effect of chemotherapy, but not related to cystitis or the urinary system.

Nursing Concepts and Clinical Reasoning

Nurses administering cyclophosphamide must monitor for urinary symptoms and encourage aggressive hydration, as dilution of urine limits bladder contact with toxic metabolites. Hematuria—especially with dysuria—represents significant bladder irritation. Immediate assessment, provider notification, and initiation of bladder-protective strategies (such as mesna if not already administered) are evidence-based priorities. Early recognition prevents complications like severe hemorrhage or bladder fibrosis.

Pathophysiology: Cyclophosphamide is metabolized in the liver, producing acrolein, a metabolite that is excreted in urine and is directly toxic to bladder epithelium. The inflammation and bleeding (hemorrhagic cystitis) present clinically as dysuria and hematuria. This mechanism is a critical difference between hemorrhagic cystitis and other chemotherapy side effects.

Clinical Pearl: Always remember the mnemonic “C for Cyclophosphamide and Cystitis.” Visible blood plus dysuria in anyone receiving cyclophosphamide must trigger urine assessments and rapid provider notification.

Key Nursing Standard: According to current guidelines and summarized in Udan’s Nursing Review Book (Green Book), monitoring urine for hematuria and teaching patients to report any urinary discomfort or bloody urine is standard for all patients on cyclophosphamide.

Silvestri, L. A. (2017). Saunders Comprehensive Review for the NCLEX-RN Examination (7th ed.). Elsevier.

References and further reading

PRC Enhanced Table of Specifications for the Nurses Licensure Examination official
The current public competency and cognitive-level blueprint, effective from the November 2025 NLE onward.
Tangerine Prep PNLE Reviewer question bank
The live source for the published question count, question previews, rationales, and inventory distributions on this page.

How this page is built

The counts and distributions on this page come from Tangerine Prep's live published question bank. The source inventory was last updated on August 12, 2026.

The questions are original PNLE-style practice items, not recalled or leaked board questions. Topic scope follows Tangerine's pedagogical taxonomy and is mapped to the PRC 2025 Enhanced Table of Specifications, effective from the November 2025 NLE onward. Exact topic distribution varies by exam form.